News
Article
Author(s):
If you weren’t able to attend the 2023 Society of Dermatology Physicians Fall Conference or want to review our latest coverage and interviews, our full recap has you covered.
The conference aimed at providing dermatology physician assistants with the latest in the field begins tomorrow in Nashville, Tennessee.
Click here to answer today's poll.
When sessions, late-breaking research, and more conclude at SDPA Fall 2023, there is no shortage of things to do in Nashville.
Mast spoke with Dermatology Times about her conference workshop, what she's looking forward to ahead of this week's SDPA conference, and the importance of always maintaining a passion for patients.
Re-treatment 12 months after initial hyaluronic acid filler treatment resulted in further infraorbital rejuvenation.
The most common conditions or concerns patients reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.
Renata Block, MMS, PA-C, delves into the important and ever-evolving role of physician assistants in dermatology.
A post hoc analysis evaluated the safety, efficacy, and tolerability of IDP-126 gel in Black patients with moderate to severe acne, of which there are limited data and literature describing its outcomes in this patient population.
Orit Markowitz, MD, discusses pearls her SDPA fall conference sessions, "Melanoma Diagnosis, Outcomes and Survival," and "Advanced Conditions."
Catch up on coverage from the first day of the 2023 SDPA Fall Dermatology Conference.
Robyn Siperstein, MD, FAAD, reviews highlights and takeaways from her SDPA Fall 2023 sessions discussing considerations in cosmetic dermatology, thought-changing research in aesthetics, and more.
More than 80% of patients did not experience an increase in number of draining tunnels associated with HS by week 52.
Joe Cari, MPAS, PA-C, spoke to SDPA Fall Conference attendees about the importance of maximizing the patient journey from arrival to check out and beyond.
Tazarotene was significantly less irritating to the skin than trifarotene and numerically less irritating than adapalene, according to a poster presented at SDPA Fall 2023.
Douglas DiRuggiero, DMSc, PA-C, presented a comprehensive session at the SDPA fall conference on treatment selection for patients with psoriasis.
A poster presented at SDPA’s fall conference revealed key insights into the importance of close monitoring and preventative measures in patients with cSCC.
Catch up on coverage from the second day of the 2023 SDPA Fall Dermatology Conference.
Lisa Swanson, MD, PhD, delves into clinical pearls from her SDPA fall conference sessions on infantile hemangiomas and challenging cases in pediatric dermatology.
Once daily application of tapinarof cream 1% rapidly improved itch in adult patients with varying plaque psoriasis diseases severity, according to a poster presented at SDPA’s fall conference.
Olushola Akinshemoyin Vaughn, MD, shared clinical pearls from her work in a vulvar dermatology clinic at the 2023 SDPA fall conference.
Rebecca Vasquez, MD, presented a session on common, overlapping, and complex pigmented dermatoses.
Ami Greene, MD, discusses her beginner and intermediate SDPA fall conference sessions on dermoscopy.
Investigators said that additional, larger studies are needed to assess the safety of live attenuated vaccine administration for pediatric AD patients being treated with dupilumab.
Catch up on coverage from the third day of the 2023 SDPA Fall Dermatology Conference.
The study was presented in a poster at the 2023 SDPA Fall Conference in Nashville, TN.
Ted Rosen, MD, presented a session comprehensively discussing common dermatoses characterized by itch and pruritus.
Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.
Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.
Catch up on coverage from the fourth and final day of the 2023 SDPA Fall Dermatology Conference.
Click here to answer today's poll.